Neuland Laboratories Ltd: Why Is It Outperforming Nifty 500?

Neuland Laboratories Ltd's latest quarterly results (Mar 2026) show

• PAT Growth YoY: +660.7% (turning around (inflection up))
• Revenue Growth YoY: +136.6%
• Operating Margin: 40.0% (volatile)

Neuland Laboratories Ltd's profit is growing with an turning around (inflection up) trend.

• PAT Growth YoY: +660.7% (latest quarter)
• PAT Growth QoQ: +419.5% (sequential)
• 3-Year PAT CAGR: +30.4%
• Trend: Turning around (inflection up) — consistent growth pattern

Neuland Laboratories Ltd's revenue growth trend is turning around (inflection up).

• Revenue Growth YoY: +136.6%
• Revenue Growth QoQ: +76.4% (sequential)
• 3-Year Revenue CAGR: +19.3%

Neuland Laboratories Ltd's operating margin is volatile.

• Current OPM: 40.0%
• OPM Change YoY: +24.0% basis points
• OPM Change QoQ: +22.0% basis points

Neuland Laboratories Ltd's long-term compounding rates

• 3-Year Profit CAGR: +30.4%
• 3-Year Revenue CAGR: +19.3%

Neuland Laboratories Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.

• YoY Acceleration: +159.8% bps
• Sequential Acceleration: +100.0% bps

Neuland Laboratories Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹365 Cr
• TTM PAT Growth: +39.9% YoY
• TTM Revenue: ₹2,000 Cr
• TTM Revenue Growth: +37.0% YoY
• TTM Operating Margin: 28.6%

Neuland Laboratories Ltd appears significantly overvalued based on our fair value analysis.

• Valuation Signal: Significantly Overvalued
• Current PE: 63.3x
• Price-to-Book: 12.3x

Neuland Laboratories Ltd's current PE ratio is 63.3x.

• Current PE: 63.3x
• Market Cap: 23.0K Cr
• Dividend Yield: 0.19%

Neuland Laboratories Ltd's current PE is 63.3x.

• Current PE: 63.3x
• Valuation Assessment: Significantly Overvalued

Neuland Laboratories Ltd's price-to-book ratio is 12.3x.

• Price-to-Book (P/B): 12.3x
• Book Value per Share: ₹1461
• Current Price: ₹17961

Neuland Laboratories Ltd is rated Average with a fundamental score of 53/100. This score is calculated from objective financial metrics

• Revenue Growth YoY: +136.6% (10% weight)
• PAT Growth YoY: +660.7% (10% weight)
• PAT Growth QoQ: +419.5% (10% weight)
• Margins stable (10% weight)

Neuland Laboratories Ltd has a debt-to-equity ratio of N/A.

• Total Debt: ₹301 Cr

Neuland Laboratories Ltd's return ratios over recent years

• FY2024: ROCE 33.0%
• FY2025: ROCE 19.0%
• FY2026: ROCE 27.0%

Neuland Laboratories Ltd's operating cash flow is positive (FY2026).

• Cash from Operations (CFO): ₹347 Cr
• Free Cash Flow (FCF): ₹-77 Cr
• CFO/PAT Ratio: 95% (strong cash conversion)

Neuland Laboratories Ltd's current dividend yield is 0.19%.

• Dividend Yield: 0.19%
• Current Price: ₹17961

Neuland Laboratories Ltd's shareholding pattern (Mar 2026)

• Promoters: 32.6%
• FII (Foreign): 20.5%
• DII (Domestic): 15.8%
• Public: 31.1%

Neuland Laboratories Ltd's promoter holding has remained stable recently.

• Current Promoter Holding: 32.6% (Mar 2026)
• Previous Quarter: 32.6% (Dec 2025)
• Change: 0.00% (stable)

Neuland Laboratories Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.

Neuland Laboratories Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.

Based on quantitative research signals, here is why Neuland Laboratories Ltd may be worth studying

• Earnings growing at +660.7% YoY
• Cash flow is positive — CFO ₹347 Cr

Neuland Laboratories Ltd investment thesis summary:

Neuland Laboratories Ltd's forward outlook based on current data signals

• Earnings Trend: turning around (inflection up)
• Revenue Trend: turning around (inflection up)
• Margin Trend: volatile
• Valuation: Significantly Overvalued